Clinical Trials Network, Ohio Valley Node U10DA013732

临床试验网络，俄亥俄谷节点 U10DA013732

• 批准号: 7983629
• 负责人: EUGENE C. SOMOZA
• 金额: $ 117.29万
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7983629
• 关键词: AIDS/HIV problem; Accident and Emergency department; Agreement; Area; Award; Bilateral; Buprenorphine; Caring; Characteristics; Clinic; Clinical; Clinical Trials Network; Collaborations; Communication; Communities; Conduct Clinical Trials; Contracts; Data; Dose; Emergency Medicine; Evidence based practice; Goals; Health Personnel; Hospitals; Kentucky; Leadership; Letters; Literature; Mission; Monitor; National Institute of Drug Abuse; Office of Administrative Management; Ohio; Opiate Addiction; Opioid; Participant; Patients; Pharmaceutical Preparations; Primary Health Care; Procedures; Progress Reports; Protocols documentation; Research; Research Personnel; Research Training; Resource Sharing; Structure; Substance abuse problem; Technology Transfer; Telemedicine; Tennessee; Training; Translational Research; U-Series Cooperative Agreements; Visit; West Virginia; Work; addiction; base; design; experience; human subject protection; improved; member; public health relevance; success; treatment program

DESCRIPTION (provided by applicant): From the beginning of its membership in NIDA's Clinical Trials Network (CTN) in 2000, the Ohio Valley Node (OVN) has been an effective, enthusiastic, and energetic node that has excelled in providing scientific and administrative leadership, in collaborating with other nodes and with NIDA and contract staff, and in disseminating information about evidence-based practices and the results of CTN studies. The OVN's Community Treatment Programs (CTPs) and its Regional Research and Training Center (RRTC) have worked together to create a node in which the CTN's goal of bilateral communication/collaboration between researchers and treatment providers has been fully realized. The success in integrating all members of this geographically dispersed node into a unified whole, together with the strong commitment of the Node PI, CTP PIs, and RRTC staff to full participation in the CTN, have enabled the OVN to be extremely productive throughout its membership in the CYN. The OVN has an experienced staff, including several RRTC and CTP PIs who have been with the OVN since its formation. The OVN continues to collaborate with a growing number of CTPs which have a variety of patient characteristics and extend over a broad geographical range now encompassing the entire Midwest (12 states) and the Upper-South states of Kentucky, Tennessee, and West Virginia. The 23 OVN CTPs, which together receive more than 100,000 patient visits a year, will contribute significantly to the number and variety of potential participants for CTN studies. The OVN administrative and management plans for the next five years capitalize on the strengths of the OVN: experience, teamwork, and varied areas of expertise (including HIV/AIDS, emergency medicine, integration of addiction treatment into primary care, and telemedicine), so the OVN can continue to contribute scientific leadership and excellence in developing/conducting CTN protocols. The OVN has detailed a research agenda designed to improve opioid dependence treatment by optimizing medication-assisted treatment and expanding office-based opioid treatment. Already cooperating actively with the four Addiction Technology and Transfer Centers (ATTCs) associated with the states covered by the OVN, the Node plans to strengthen relationships with other networks (e.g., Cincinnati Center for Clinical & Translational Science & Training). PUBLIC HEALTH RELEVANCE: To further the goal of expanding substance abuse care and research into non-traditional settings, Ohio Valley Node Community Treatment Programs now include an HIV/AIDS clinic, two primary care centers, and two hospital emergency departments. The Ohio Valley Node's research agenda is designed to improve opioid dependence treatment by optimizing medication-assisted treatment and expanding office-based opioid treatment, including a new mechanism for dosing buprenorphine which would reduce diversion.

DESCRIPTION (provided by applicant): From the beginning of its membership in NIDA's Clinical Trials Network (CTN) in 2000, the Ohio Valley Node (OVN) has been an effective, enthusiastic, and energetic node that has excelled in providing scientific and administrative leadership, in collaborating with other nodes and with NIDA and contract staff, and in disseminating information about evidence-based practices and the results of CTN studies. OVN的社区治疗计划（CTP）及其区域研究与培训中心（RRTC）共同创建了一个节点，在该节点中，CTN的研究人员与治疗提供者之间的双边交流/协作目标已充分实现。将该地理位置分散的节点的所有成员的成功纳入统一的整体，以及节点PI，CTP PIS和RRTC工作人员的坚定承诺使OVN在CYN成员的整个成员中都非常有生产力。 OVN拥有一位经验丰富的员工，其中包括自成立以来与OVN一起使用的几个RRTC和CTP PI。 OVN继续与越来越多的CTP合作，这些CTP具有多种患者特征，并在广泛的地理范围内扩展了整个中西部（12个州）和肯塔基州，田纳西州和西弗吉尼亚州的上层州。每年共有100,000多次患者就诊的23个OVN CTP将对CTN研究的潜在参与者的数量和种类做出重大贡献。 OVN行政和管理计划未来五年的OVN优势：经验，团队合作和各种专业知识领域（包括艾滋病毒/艾滋病，急诊医学，成瘾治疗融入初级保健和远程医疗），因此OVN可以继续在开发/进行CTN协议方面继续为科学领导和卓越的贡献。 OVN详细介绍了旨在通过优化药物辅助治疗和扩大基于办公室的阿片类药物治疗的研究议程。节点已经与与OVN涵盖的州相关的四个成瘾技术和转移中心（ATTC）积极合作，该节点计划加强与其他网络的关系（例如，辛辛那提临床与转化科学与培训中心）。 公共卫生相关性：为了进一步将药物滥用护理和研究扩展到非传统环境中，俄亥俄州谷节点社区治疗计划现在包括艾滋病毒/艾滋病诊所，两个初级保健中心和两个医院急诊室。俄亥俄州谷节点的研究议程旨在通过优化药物辅助治疗和扩大基于办公室的阿片类药物治疗，包括一种新的丁丙诺啡的机制来改善阿片类药物依赖治疗，这将减少转移。